Immunoassay Market: Growth, Size, Share, and Trends
Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, CLIA, Western Blot), Specimen (Blood, Saliva, Urine), Application (Infectious Diseases, Endocrinology), End User (Hospitals & Clinics, Laboratories) - Global Forecast to 2030
USD 47.76 BN
MARKET SIZE, 2030
CAGR 6.1%
(2025-2030)
494
REPORT PAGES
570
MARKET TABLES
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The immunoassay market is projected to reach USD 47.76 billion by 2030 from USD 35.53 billion in 2025, at a CAGR of 6.1%. It is driven by the rising prevalence of chronic and infectious diseases, growing demand for early disease diagnosis, advancements in automation and high-throughput technologies, and increasing adoption of immunoassay-based point-of-care testing.
KEY TAKEAWAYS
-
BY PRODUCTThe immunoassay market comprises of reagents & kits, and analyzers. The demand for reagents and kits is driven by their recurring use in diagnostic testing, while analyzers are gaining traction due to increasing automation and the need for high-throughput laboratory workflows.
-
BY TECHNOLOGYKey technologies include enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassay (CLIA), immunofluorescence assay (IFA), rapid tests, enzyme-linked immunospot (ELISpot), western blotting , and other technologies. Technological advancement drives growth across ELISA, CLIA, IFA, and rapid tests, with a growing shift toward highly sensitive, specific, and multiplexing platforms for faster and more accurate diagnostics.
-
BY SPECIMENKey specimens include blood, saliva, urine, and other specimens. Blood remains the most widely used specimen due to its reliability and accuracy, while non-invasive specimens like saliva and urine are gaining momentum for convenient and patient-friendly diagnostic testing.
-
BY APPLICATIONKey applications include infectious diseases, endocrinology, oncology, bone & mineral disorders, cardiology, blood screening, autoimmune disorders, allergy diagnostics, drug monitoring & testing, newborn screening, and other applications. Expanding use of immunoassays in infectious disease detection, oncology, endocrinology, and drug monitoring is fueled by rising disease prevalence, the need for early diagnosis, and personalized treatment approaches.
-
BY END USERThe immunoassay market comprises hospitals & clinics, clinical laboratories, blood banks, and home care end users. Hospitals, clinics, and laboratories drive demand through routine diagnostics and large-scale testing, while the growing adoption of point-of-care and home-based immunoassay devices enhances accessibility and rapid result delivery.
-
BY REGIONThe immunoassay market covers North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The immunoassay market is experiencing global growth driven by strong healthcare infrastructure and technological innovation in North America and Europe, rapid diagnostic expansion and government investments in Asia-Pacific, improving healthcare access and affordability in Latin America, and increasing disease prevalence and adoption of point-of-care testing in the Middle East and Africa.
-
COMPETITIVE LANDSCAPEMajor market players have adopted both organic and inorganic strategies, including partnerships and investments. F. Hoffmann-La Roche Ltd. (Switzerland) expanded its collaboration with Janssen Biotech Inc. (Janssen), which broadened the opportunities for Roche and Janssen to collaborate across multiple companion diagnostics technologies, including immunohistochemistry (IHC), digital pathology, NGS, polymerase chain reaction, and immunoassays.
The immunoassay market is growing steadily, driven by the increasing prevalence of chronic and infectious diseases, rising demand for early and accurate diagnostics, and expanding use in therapeutic drug monitoring and oncology testing. Technological innovations such as high-sensitivity chemiluminescence, multiplex assays, and automated platforms are enhancing diagnostic accuracy and efficiency. Strategic collaborations, investments in R&D for novel biomarkers, and the adoption of point-of-care immunoassay devices are transforming the landscape, making precision, automation, and accessibility the key drivers of market growth.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The impact on healthcare providers’ business arises from patient trends and diagnostic disruptions. Hospitals, clinics, and laboratories, clients of immunoassay manufacturers, serve applications like infectious disease, oncology, and drug monitoring. Shifts such as rising disease prevalence, early-diagnosis demand, and point-of-care adoption affect end-user revenues, which in turn influence immunoassay manufacturers’ revenues, driving investment, innovation, and market expansion strategies globally.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
Level
-
Increasing incidence of chronic and infectious diseases
-
Increasing adoption of immunoassay-based POC and rapid testing
RESTRAINTS
Impact
Level
Level
-
Stringent requirements for approval of immunoassay instruments and consumables
-
Technical hurdles of immunoassay kits
OPPORTUNITIES
Impact
Level
Level
-
Improving immunoassay diagnostic technologies
-
Increasing growth opportunities in emerging economies
CHALLENGES
Impact
Level
Level
-
Design challenges and low quality of antibodies
-
Dearth of skilled professionals
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Increasing incidence of chronic and infectious diseases
The rising incidence of chronic and infectious diseases is a key driver for the immunoassay market, fueling the demand for timely and accurate diagnostics. The growing prevalence of conditions like cancer, diabetes, cardiovascular disorders, and infectious outbreaks necessitates advanced immunoassay testing for early detection, monitoring, and effective patient management.
Restraint: Stringent requirements for approval of immunoassay instruments and consumables
Stringent regulatory requirements for the approval of immunoassay instruments and consumables pose a significant restraint on market growth. Compliance with standards set by authorities such as the FDA, EMA, and IVDR involves extensive validation, clinical trials, and documentation, increasing time-to-market and development costs for manufacturers, which can delay product launches and limit the introduction of innovative diagnostic solutions.
Opportunity: Improving immunoassay diagnostic technologies
Advancements in immunoassay diagnostic technologies are creating significant opportunities in the market, driven by the development of high-sensitivity, automated, and multiplex platforms. Innovations such as chemiluminescence, point-of-care testing, and microfluidics enhance accuracy, speed, and efficiency, enabling early disease detection, better patient monitoring, and personalized treatment, thereby expanding adoption across hospitals, laboratories, and home-care settings.
Challenge: Design challenges and low quality of antibodies
Design challenges and low-quality antibodies remain significant hurdles in the immunoassay market. Poor antibody specificity or stability can lead to inaccurate results, reduced assay sensitivity, and increased variability across tests. These limitations hinder the development of reliable assays, raise validation costs, and slow adoption of new immunoassay technologies, impacting overall market growth and manufacturer credibility.
Immunoassay Market: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Architect and Alinity immunoassay platforms for infectious disease, oncology, and endocrinology testing | High-throughput testing, automated workflows, rapid and accurate results, broad test menu |
 |
Elecsys immunoassays for diagnostics in oncology, cardiovascular, and infectious diseases | Sensitive and specific assays, integration with cobas analyzers, and reliable clinical decision support |
 |
Beckman Coulter immunoassay systems for routine clinical and specialty testing | Efficient laboratory automation, consistent assay performance, reduced turnaround time |
 |
ADVIA Centaur and Atellica platforms for infectious disease, cardiology, and hormone testing | Fast, accurate, and scalable testing; flexible sample handling; comprehensive assay portfolio |
 |
Bio-Plex and Platelia immunoassays for autoimmune disorders, infectious diseases, and research applications | Multiplexing capability, high sensitivity, customizable assays, reliable research, and clinical results |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The immunoassay market ecosystem consists of raw material suppliers (Abcam, Medix Biochemica), device manufacturers (Abbott, Roche, Danaher, Siemens Healthineers, Bio-Rad), and end users (Hospitals & Clinics, Clinical Laboratories, Blood Banks, and Home Care Settings). Materials are processed into high-sensitivity immunoassay kits and analyzers. End users drive demand for accuracy, speed, and reliability, while manufacturers deliver innovative, automated, and multiplex testing solutions. Collaboration across the value chain is critical for technological advancement and market expansion.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Immunoassay Market, by Product
In 2024, the reagents & kits segment dominated the immunoassay market by product, driven by their essential role in ensuring assay accuracy and sensitivity across applications such as infectious disease, oncology, endocrinology, and therapeutic drug monitoring. These kits are widely used in hospitals, clinical laboratories, and blood banks, supporting consistent demand. The analyzers segment is gaining momentum due to growing adoption of automation and high-throughput testing, enabling rapid, reliable results, reducing manual errors, and improving laboratory workflow and diagnostic efficiency.
Immunoassay Market, by Technology
In 2024, the ELISA (enzyme-linked immunosorbent assay) segment dominated the immunoassay market by technology, owing to its high sensitivity, specificity, and wide applicability across diagnostics, including infectious diseases, oncology, and endocrinology. Its standardized protocols, cost-effectiveness, and compatibility with high-throughput laboratories make it the preferred choice among hospitals and clinical laboratories. Other technologies, such as CLIA, IFA, rapid tests, ELISpot, and Western Blotting, are witnessing steady adoption due to advancements in automation, multiplexing, and point-of-care testing, catering to specialized diagnostic needs and research applications.
Immunoassay Market, by Specimen
In 2024, the blood segment accounted for the largest share in the immunoassay market by specimen, driven by its reliability, ease of collection, and ability to provide accurate and reproducible results for a wide range of diagnostic applications, including infectious diseases, oncology, and endocrinology. Non-invasive specimens such as saliva and urine are increasingly adopted for patient-friendly testing, home-based diagnostics, and therapeutic monitoring, while other specimens like cerebrospinal fluid and tissue samples are used for specialized clinical and research applications.
Immunoassay Market, by Application
In 2024, the infectious diseases segment held the largest share in the immunoassay market by application, driven by the rising prevalence of viral and bacterial infections and the critical need for rapid, accurate diagnostics. Other applications, including endocrinology, oncology, bone and mineral disorders, cardiology, blood screening, autoimmune disorders, allergy diagnostics, drug monitoring, and newborn screening, are witnessing steady growth due to increasing disease awareness, personalized medicine approaches, and the adoption of immunoassay testing for early detection, monitoring, and treatment management.
Immunoassay Market, by End User
In 2024, the hospitals & clinics segment accounted for the largest share in the immunoassay market by end user, driven by the high volume of routine and specialized diagnostic testing performed in these settings. Clinical laboratories are increasingly adopting immunoassay platforms for high-throughput and automated testing, while blood banks rely on immunoassays for screening infectious diseases. Home care settings are witnessing growing demand for patient-friendly, point-of-care immunoassay solutions, enabling convenient monitoring and early disease detection.
REGION
Asia Pacific to be fastest-growing region in global immunoassay market during forecast period
The Asia Pacific region is estimated to register the highest CAGR in the immunoassay market, driven by rapidly expanding healthcare infrastructure, increasing government investments in diagnostic facilities, and rising awareness of early disease detection. The growing prevalence of infectious and chronic diseases, coupled with the adoption of advanced immunoassay technologies such as automated analyzers and point-of-care testing, is fueling market growth. Emerging economies like China and India are witnessing strong demand from hospitals, clinical laboratories, and home care settings, supporting robust regional expansion.
Immunoassay Market: COMPANY EVALUATION MATRIX
In the immunoassay market, Abbott (Star) holds a leading position with a comprehensive portfolio of immunoassay platforms, high-sensitivity reagents, and extensive global distribution, making it a preferred choice for hospitals, clinical laboratories, and blood banks. Revvity (Emerging Leader) is gaining traction through innovative assay development, a focus on multiplex and automated solutions, and an expanding presence in emerging markets. While Abbott benefits from scale, brand recognition, and a broad test menu, Revvity shows strong growth potential as demand rises for rapid, accurate, and accessible diagnostic testing worldwide.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 34.46 Billion |
| Market Forecast in 2030 (value) | USD 47.76 Billion |
| Growth Rate | CAGR of 6.1% from 2025 to 2030 |
| Years Considered | 2023–2030 |
| Base Year | 2024 |
| Forecast Period | 2025–2030 |
| Units Considered | Value (USD Million/Billion), Volume (Billion Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
WHAT IS IN IT FOR YOU: Immunoassay Market REPORT CONTENT GUIDE
RECENT DEVELOPMENTS
- February 2025 : bioMérieux partnered with Vall d'Hebron to advance research & development in the areas of infectious diseases, data surveillance, and laboratory automation.
- January 2025 : bioMérieux entered into an agreement to acquire SpinChip Diagnostics ASA (“SpinChip”), a privately held Norwegian diagnostics company that has developed a game-changing immunoassay diagnostics platform. The small benchtop analyzer was well adapted to near-patient testing as it could deliver a result from a whole blood sample within 10 minutes with the same high-sensitivity performance as the laboratory instruments.
- April 2024 : Bio-Rad entered into a collaboration agreement with Oncocyte Corporation to develop and commercialize transplant monitoring products, leveraging Bio-Rad’s Droplet Digital PCR (ddPCR) instruments and reagents for enhanced precision in transplant diagnostics.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
39
2
RESEARCH METHODOLOGY
44
3
EXECUTIVE SUMMARY
57
4
PREMIUM INSIGHTS
63
5
MARKET OVERVIEW
Surging healthcare demands and biotech growth drive immunoassay market amidst regulatory and technical challenges.
67
5.1
INTRODUCTION
5.2
MARKET DYNAMICS
5.2.1
DRIVERS
5.2.1.1
INCREASING INCIDENCE OF CHRONIC AND INFECTIOUS DISEASES
5.2.1.2
INCREASED DEMAND FOR BLOOD DONATIONS IN HEALTHCARE SYSTEMS AND SURGICAL PROCEDURES
5.2.1.3
GROWTH IN BIOTECHNOLOGY & BIOPHARMACEUTICAL INDUSTRIES
5.2.1.4
INCREASING ADOPTION OF IMMUNOASSAY-BASED POC AND RAPID TESTING
5.2.1.5
SUPPORTIVE GOVERNMENT REGULATORY POLICIES AND INITIATIVES
5.2.1.6
INCREASED CONSUMPTION OF DRUGS, ALCOHOL, AND CANNABIS
5.2.2
RESTRAINTS
5.2.2.1
STRINGENT REQUIREMENTS FOR APPROVAL OF IMMUNOASSAY INSTRUMENTS AND CONSUMABLES
5.2.2.2
TECHNICAL HURDLES OF IMMUNOASSAY KITS
5.2.3
OPPORTUNITIES
5.2.3.1
INCREASING GROWTH OPPORTUNITIES IN EMERGING ECONOMIES
5.2.3.2
FOCUS ON IMPORTANCE OF COMPANION DIAGNOSTICS
5.2.3.3
DEVELOPMENT OF CONDITION-SPECIFIC BIOMARKERS AND TESTS
5.2.3.4
INTEGRATION OF MICROFLUIDICS IN IMMUNOASSAYS
5.2.3.5
IMPROVING IMMUNOASSAY DIAGNOSTIC TECHNOLOGIES
5.2.4
CHALLENGES
5.2.4.1
DESIGN CHALLENGES AND LOW QUALITY OF ANTIBODIES
5.2.4.2
DEARTH OF SKILLED PROFESSIONALS
5.3
REGULATORY ANALYSIS
5.3.1
REGULATORY FRAMEWORK
5.3.1.1
NORTH AMERICA
5.3.1.2
EUROPE
5.3.1.3
ASIA PACIFIC
5.3.1.4
MIDDLE EAST
5.3.1.5
LATIN AMERICA
5.3.1.6
AFRICA
5.3.2
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.4
TECHNOLOGY ANALYSIS
5.4.1
KEY TECHNOLOGIES
5.4.1.1
ELISA
5.4.2
ADJACENT TECHNOLOGIES
5.4.2.1
MICROFLUIDICS AND MINIATURIZED PLATFORMS
5.4.3
COMPLEMENTARY TECHNOLOGIES
5.4.3.1
LATERAL FLOW ASSAYS
5.5
TRADE ANALYSIS
5.5.1
IMPORT DATA FOR HS CODE 382200, 2019–2024
5.5.2
EXPORT DATA FOR HS CODE 382200, 2019–2024
5.6
PATENT ANALYSIS
5.7
VALUE CHAIN ANALYSIS
5.8
SUPPLY CHAIN ANALYSIS
5.9
ECOSYSTEM ANALYSIS
5.9.1
ROLE IN ECOSYSTEM
5.10
PORTER’S FIVE FORCES ANALYSIS
5.10.1
INTENSITY OF COMPETITIVE RIVALRY
5.10.2
BARGAINING POWER OF SUPPLIERS
5.10.3
BARGAINING POWER OF BUYERS
5.10.4
THREAT OF SUBSTITUTES
5.10.5
THREAT OF NEW ENTRANTS
5.11
KEY STAKEHOLDERS & BUYING CRITERIA
5.11.1
KEY STAKEHOLDERS IN BUYING PROCESS
5.11.2
KEY BUYING CRITERIA
5.12
KEY CONFERENCES & EVENTS, 2025–2026
5.13
PRICING ANALYSIS
5.13.1
AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY KEY PLAYER, 2022–2024
5.13.2
AVERAGE SELLING PRICE TREND OF IMMUNOASSAY ANAYZERS, BY REGION, 2022–2024
5.13.3
AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY TYPE, 2022–2024
5.14
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.15
CASE STUDY ANALYSIS
5.15.1
PORTABLE MICROFLUIDIC CHEMILUMINESCENT IMMUNOASSAY TO BE USED FOR RAPID COVID-19 IMMUNITY MONITORING
5.15.2
MICROFLUIDIC-BASED IMMUNOASSAY TO HELP IN EARLY CANCER DETECTION
5.15.3
LUMINEX-BASED MULTIPLEX IMMUNOASSAY TO AID AUTOIMMUNE DISEASE PROFILING
5.16
INVESTMENT & FUNDING SCENARIO
5.17
IMPACT OF AI/GEN AI ON IMMUNOASSAY MARKET
5.17.1
MARKET POTENTIAL FOR IMMUNOASSAY PRODUCTS
5.17.2
FUTURE OF AI/GEN AI IN IMMUNOASSAY MARKET
5.18
IMPACT OF 2025 US TARIFF ON IMMUNOASSAY MARKET
5.18.1
INTRODUCTION
5.18.2
KEY TARIFF RATES
5.18.3
PRICE IMPACT ANALYSIS
5.18.4
IMPACT ON COUNTRY/REGION
5.18.4.1
NORTH AMERICA
5.18.4.2
EUROPE
5.18.4.3
ASIA PACIFIC
5.18.5
IMPACT ON END-USE INDUSTRIES
5.18.5.1
HOSPITALS & CLINICS
5.18.5.2
CLINICAL LABORATORIES
5.18.5.3
BLOOD BANKS
5.18.5.4
HOME CARE SETTINGS
6
IMMUNOASSAY MARKET, BY PRODUCT
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 71 Data Tables
118
6.1
INTRODUCTION
6.2
REAGENTS & KITS
6.2.1
ELISA REAGENTS & KITS
6.2.1.1
INCREASED USE OF HIGH-THROUGHPUT SCREENING IN DRUG DISCOVERY PROGRAMS TO DRIVE SEGMENT
6.2.2
RAPID TEST REAGENTS & KITS
6.2.2.1
HIGH DEMAND FOR PRELIMINARY SCREENING TESTS IN REMOTE AREAS TO PROPEL SEGMENT GROWTH
6.2.3
ELISPOT REAGENTS & KITS
6.2.3.1
HIGH SENSITIVITY, FUNCTIONALITY, AND ADAPTABILITY OF ELISPOT TECHNOLOGY TO AID SEGMENT GROWTH
6.2.4
CLIA REAGENTS & KITS
6.2.4.1
BETTER DIAGNOSIS AND HIGHER SPECIFICITY TO AUGMENT SEGMENT GROWTH
6.2.5
IFA REAGENTS & KITS
6.2.5.1
BETTER ADAPTABILITY IN CLINICAL DIAGNOSTICS TO SUPPORT SEGMENT GROWTH
6.2.6
WESTERN BLOT REAGENTS & KITS
6.2.6.1
WESTERN BLOT REAGENTS & KITS TO BE CONSIDERED GOLD STANDARD FOR INFECTIOUS DISEASE TEST RESULT VALIDATION
6.2.7
OTHER REAGENTS & KITS
6.3
ANALYZERS
6.3.1
IMMUNOASSAY ANALYZERS MARKET, BY TYPE
6.3.1.1
OPEN-ENDED SYSTEMS
6.3.1.2
CLOSED-ENDED SYSTEMS
6.3.2
IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE
6.3.2.1
RENTAL PURCHASE
6.3.2.2
OUTRIGHT PURCHASE
7
IMMUNOASSAY MARKET, BY TECHNOLOGY
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 44 Data Tables
160
7.1
INTRODUCTION
7.2
ELISA
7.2.1
BETTER SENSITIVITY AND QUICKER RESULTS TO DRIVE MARKET
7.3
CLIA
7.3.1
GOOD SPECIFICITY, WIDE LINEAR RANGE, AND HIGH SENSITIVITY TO AID MARKET GROWTH
7.4
IFA
7.4.1
IFA TO DIAGNOSE ANTIBODIES AND ANALYZE SMALL BIOLOGICAL AND NON-BIOLOGICAL MOLECULES
7.5
RAPID TESTS
7.5.1
FASTER RESULTS AND EASE OF USE TO DRIVE ADOPTION IN POINT-OF-CARE DIAGNOSIS AND EMERGENCY CARE SETTINGS
7.6
WESTERN BLOTTING
7.6.1
ABILITY TO DETECT AND CONFIRM ANTIBODIES OF RETROVIRUSES TO SPUR MARKET GROWTH
7.7
ELISPOT
7.7.1
HIGH SENSITIVITY, SPECIFICITY, AND VERSATILITY TO PROPEL MARKET GROWTH
7.8
OTHER TECHNOLOGIES
8
IMMUNOASSAY MARKET, BY SPECIMEN
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 26 Data Tables
187
8.1
INTRODUCTION
8.2
BLOOD
8.2.1
HIGH RELIABILITY AND INCREASED NEED DURING SURGICAL PROCEDURES TO AID MARKET GROWTH
8.3
SALIVA
8.3.1
ADVANCEMENTS IN IMMUNOASSAY-BASED SALIVA TESTS TO AUGMENT MARKET GROWTH
8.4
URINE
8.4.1
INCREASING USE BY LAW ENFORCEMENT AGENCIES AND RISING PREVALENCE OF KIDNEY DISEASES TO FAVOR MARKET GROWTH
8.5
OTHER SPECIMENS
9
IMMUNOASSAY MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 67 Data Tables
204
9.1
INTRODUCTION
9.2
INFECTIOUS DISEASES
9.2.1
RISING PREVALENCE OF CHRONIC INFECTIOUS DISEASES TO DRIVE MARKET
9.3
ENDOCRINOLOGY
9.3.1
RISING INCIDENCE OF DIABETES TO AUGMENT MARKET GROWTH
9.4
CARDIOLOGY
9.4.1
HIGH BURDEN OF CARDIOVASCULAR DISEASES TO SUPPORT MARKET GROWTH
9.5
AUTOIMMUNE DISORDERS
9.5.1
HIGH INCIDENCE AND PREVALENCE OF AUTOIMMUNE DISEASES TO AUGMENT MARKET GROWTH
9.6
ALLERGY DIAGNOSTICS
9.6.1
GROWING PREVALENCE OF ALLERGIES TO AID MARKET GROWTH
9.7
ONCOLOGY
9.7.1
RISING BURDEN OF CANCER AND GROWING EMPHASIS ON EARLY DETECTION TO PROPEL MARKET GROWTH
9.8
BONE & MINERAL DISORDERS
9.8.1
INCREASING PREVALENCE OF OSTEOPOROSIS, VITAMIN D DEFICIENCY, AND ARTHRITIS TO AID MARKET GROWTH
9.9
DRUG MONITORING & TESTING
9.9.1
RISING DRUG ABUSE AND INCREASING ILLICIT DRUG CONSUMPTION TO ACCELERATE MARKET GROWTH
9.10
BLOOD SCREENING
9.10.1
RISING EMPHASIS ON BLOOD DONATIONS TO FAVOR MARKET GROWTH
9.11
NEWBORN SCREENING
9.11.1
TECHNOLOGICAL ADVANCEMENTS AND FAVORABLE GOVERNMENT INITIATIVES TO PROPEL MARKET GROWTH
9.12
OTHER APPLICATIONS
10
IMMUNOASSAY MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 26 Data Tables
246
10.1
INTRODUCTION
10.2
HOSPITALS & CLINICS
10.2.1
GROWING PATIENT POPULATION AND RISING TESTING VOLUME TO DRIVE MARKET
10.3
CLINICAL LABORATORIES
10.3.1
INCREASING NUMBER OF ACCREDITED LABORATORIES TO DRIVE MARKET
10.4
HOME CARE SETTINGS
10.4.1
RISING UTILIZATION OF POC DIAGNOSTICS AND AT-HOME ANTIGEN DIAGNOSIS TO PROPEL MARKET GROWTH
10.5
BLOOD BANKS
10.5.1
INCREASING NUMBER OF ACCIDENTS AND RISING DEMAND FOR BLOOD DURING SURGERIES TO SPUR MARKET GROWTH
11
IMMUNOASSAY MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 16 Countries | 203 Data Tables.
264
11.1
INTRODUCTION
11.2
NORTH AMERICA
11.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2
US
11.2.2.1
US TO DOMINATE NORTH AMERICAN IMMUNOASSAY MARKET DURING FORECAST PERIOD
11.2.3
CANADA
11.2.3.1
INCREASING GOVERNMENT SUPPORT AND RISING INCIDENCE OF CHRONIC DISEASES TO AUGMENT MARKET GROWTH
11.3
EUROPE
11.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2
GERMANY
11.3.2.1
HIGH HEALTHCARE SPENDING AND FAVORABLE GOVERNMENT INITIATIVES TO PROPEL MARKET GROWTH
11.3.3
ITALY
11.3.3.1
RISING GERIATRIC POPULATION AND INCREASING CANCER PREVALENCE TO SPUR MARKET GROWTH
11.3.4
FRANCE
11.3.4.1
INCREASED USE OF POC TESTING AND FAVORABLE REIMBURSEMENT POLICIES TO BOOST MARKET GROWTH
11.3.5
SPAIN
11.3.5.1
INCREASING ADOPTION OF TECHNOLOGICALLY ADVANCED IMMUNOASSAY SYSTEMS TO AUGMENT MARKET GROWTH
11.3.6
UK
11.3.6.1
GOVERNMENT SUPPORT FOR DISEASE DIAGNOSTICS AND FAVORABLE INVESTMENT SCENARIO TO DRIVE MARKET
11.3.7
RUSSIA
11.3.7.1
INCREASING ACCESS TO QUALITY HEALTHCARE AND DEVELOPING PHARMACEUTICAL INDUSTRY TO FAVOR MARKET GROWTH
11.3.8
REST OF EUROPE
11.4
ASIA PACIFIC
11.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2
JAPAN
11.4.2.1
INCREASING INVESTMENTS IN HEALTHCARE TECHNOLOGIES AND RESEARCH ACTIVITIES TO FUEL MARKET GROWTH
11.4.3
CHINA
11.4.3.1
INCREASING GOVERNMENT INVESTMENTS AND RISING GERIATRIC POPULATION TO ACCELERATE MAKET GROWTH
11.4.4
INDIA
11.4.4.1
GROWING MEDICAL TOURISM AND IMPROVING HEALTHCARE INFRASTRUCTURE TO PROPEL MARKET GROWTH
11.4.5
AUSTRALIA
11.4.5.1
INCREASING INCIDENCE OF CANCER AND RISING FOCUS ON BLOOD DONATIONS TO FAVOR MARKET GROWTH
11.4.6
SOUTH KOREA
11.4.6.1
RISING HEALTHCARE SPENDING AND INCREASING RESEARCH INVESTMENTS TO FUEL MARKET GROWTH
11.4.7
INDONESIA
11.4.7.1
HIGH GERIATRIC POPULATION AND FAVORABLE GOVERNMENT HEALTHCARE POLICIES TO ACCELERATE MARKET GROWTH
11.4.8
REST OF ASIA PACIFIC
11.5
LATIN AMERICA
11.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2
BRAZIL
11.5.2.1
HIGH INCIDENCE OF INFECTIOUS DISEASES AND PRESENCE OF ACADEMIC & RESEARCH INSTITUTES TO BOOST MARKET GROWTH
11.5.3
MEXICO
11.5.3.1
INCREASING GERIATRIC POPULATION AND RISING POPULARITY OF MEDICAL TOURISM TO PROPEL MARKET GROWTH
11.5.4
REST OF LATIN AMERICA
11.6
MIDDLE EAST & AFRICA
11.6.1
LACK OF SKILLED LABORATORY PERSONNEL AND UNFAVORABLE REIMBURSEMENT POLICIES TO LIMIT MARKET GROWTH
12
COMPETITIVE LANDSCAPE
Discover key players' winning strategies and market dominance in the evolving immunoassay landscape.
384
12.1
INTRODUCTION
12.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1
OVERVIEW OF KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN IMMUNOASSAY MARKET
12.3
REVENUE ANALYSIS, 2020–2024
12.4
MARKET SHARE ANALYSIS, 2024
12.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
12.5.1
STARS
12.5.2
EMERGING LEADERS
12.5.3
PERVASIVE PLAYERS
12.5.4
PARTICIPANTS
12.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
12.5.5.1
COMPANY FOOTPRINT
12.5.5.2
REGION FOOTPRINT
12.5.5.3
PRODUCT FOOTPRINT
12.5.5.4
SPECIMEN FOOTPRINT
12.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
12.6.1
PROGRESSIVE COMPANIES
12.6.2
RESPONSIVE COMPANIES
12.6.3
DYNAMIC COMPANIES
12.6.4
STARTING BLOCKS
12.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
12.6.5.1
LIST OF KEY STARTUPS/SMES
12.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
12.7
COMPANY VALUATION & FINANCIAL METRICS
12.7.1
FINANCIAL METRICS
12.7.2
COMPANY VALUATION
12.8
BRAND/PRODUCT COMPARISON
12.9
COMPETITIVE SCENARIO
12.9.1
PRODUCT LAUNCHES/APPROVALS/ ENHANCEMENTS
12.9.2
DEALS
13
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
402
13.1
KEY PLAYERS
13.1.1
ABBOTT
13.1.1.1
BUSINESS OVERVIEW
13.1.1.2
PRODUCTS OFFERED
13.1.1.3
RECENT DEVELOPMENTS
13.1.1.4
MNM VIEW
13.1.2
F. HOFFMANN-LA ROCHE LTD.
13.1.3
SIEMENS HEALTHINEERS AG
13.1.4
DANAHER
13.1.5
THERMO FISHER SCIENTIFIC INC.
13.1.6
REVVITY
13.1.7
BECTON, DICKINSON AND COMPANY (BD)
13.1.8
DIASORIN S.P.A.
13.1.9
BIO-RAD LABORATORIES, INC.
13.1.10
QUIDELORTHO CORPORATION
13.1.11
BIOMÉRIEUX
13.1.12
QIAGEN
13.1.13
SYSMEX CORPORATION
13.1.14
AGILENT TECHNOLOGIES, INC.
13.1.15
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
13.2
OTHER PLAYERS
13.2.1
MERCK KGAA
13.2.2
MERIDIAN BIOSCIENCE
13.2.3
BIO-TECHNE
13.2.4
CELLABS
13.2.5
ABNOVA CORPORATION
13.2.6
J. MITRA & CO. PVT. LTD.
13.2.7
TOSOH CORPORATION (TOSOH BIOSCIENCES)
13.2.8
CELL SCIENCES
13.2.9
ENZO BIOCHEM INC.
13.2.10
CREATIVE DIAGNOSTICS
13.2.11
BOSTER BIOLOGICAL TECHNOLOGY
13.2.12
ELABSCIENCE BIONOVATON INC.
13.2.13
WAK-CHEMIE MEDICAL GMBH
13.2.14
SERA CARE
13.2.15
EPITOPE DIAGNOSTICS, INC.
13.2.16
KAMIYA BIOMEDICAL COMPANY
13.2.17
GYROS PROTEIN TECHNOLOGIES AB
13.2.18
TRIVITRON HEALTHCARE
13.2.19
INBIOS INTERNATIONAL, INC.
13.2.20
MACCURA BIOTECHNOLOGY CO., LTD.
14
APPENDIX
486
14.1
DISCUSSION GUIDE
14.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3
CUSTOMIZATION OPTIONS
14.4
RELATED REPORTS
LIST OF TABLES
TABLE 1
IMMUNOASSAY MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2
IMMUNOASSAY MARKET: KEY DATA FROM PRIMARY SOURCES
TABLE 3
IMMUNOASSAY MARKET: MARKET ASSUMPTIONS
TABLE 4
IMMUNOASSAY MARKET: RISK ANALYSIS
TABLE 5
INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
TABLE 6
PROJECTED NUMBER OF CANCER PATIENTS, BY CANCER TYPE, 2015 VS. 2018 VS. 2035 (UNITS)
TABLE 7
DETECTION TIME OF DRUG OR DRUG CLASS IN URINE TESTING
TABLE 8
ESTIMATED PERCENTAGE INCREASE IN GERIATRIC POPULATION, BY REGION, 2022 VS. 2030 VS. 2050
TABLE 9
RECENT DEVELOPMENTS IN IMMUNOASSAY MARKET, 2021–2023
TABLE 10
NEW TESTS LAUNCHED BY KEY PLAYERS, 2021–2023
TABLE 11
LAB-ON-CHIP IMMUNOASSAYS/DEVICES/SYSTEMS OFFERED BY KEY PLAYERS
TABLE 12
US: CLASSIFICATION AND RISK LEVEL OF IMMUNOASSAY PRODUCTS
TABLE 13
EUROPE: CLASSIFICATION AND RISK LEVEL OF IN-VIRTO DIAGNOSTIC DEVICES
TABLE 14
RUSSIA: CLASSIFICATION AND RISK LEVEL OF IN-VIRTO DIAGNOSTIC DEVICES
TABLE 15
JAPAN: CLASSIFICATION OF IN-VIRTO DIAGNOSTIC REAGENTS
TABLE 16
JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 17
CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 18
INDONESIA: REGISTRATION PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES
TABLE 19
SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 20
SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 21
MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 22
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 25
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 26
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 27
CONVENTIONAL IMMUNOASSAY METHODS AND TECHNIQUES
TABLE 28
RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN IMMUNOASSAY MARKET
TABLE 29
IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019–2024 (USD MILLION)
TABLE 30
EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019–2024 (USD MILLION)
TABLE 31
IMMUNOASSAY MARKET: ROLE IN ECOSYSTEM
TABLE 32
IMMUNOASSAY MARKET: PORTER’S FIVE FORCES
TABLE 33
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
TABLE 34
KEY BUYING CRITERIA, BY END USER
TABLE 35
IMMUNOASSAY MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026
TABLE 36
AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY KEY PLAYER, 2022–2024 (USD)
TABLE 37
AVERAGE SELLING PRICE TREND OF CLINICAL IMMUNOASSAY ANALYZERS, BY REGION, 2022–2024 (USD)
TABLE 38
AVERAGE SELLING PRICE TREND OF IMMUNOASSAY PRODUCTS, BY TYPE, 2022–2024 (USD)
TABLE 39
CASE STUDY 1: PORTABLE MICROFLUIDIC CHEMILUMINESCENT IMMUNOASSAY TO BE USED FOR RAPID COVID-19 IMMUNITY MONITORING
TABLE 40
CASE STUDY 2: MICROFLUIDIC-BASED IMMUNOASSAY TO HELP IN EARLY CANCER DETECTION
TABLE 41
CASE STUDY 3: LUMINEX-BASED MULTIPLEX IMMUNOASSAY TO AID AUTOIMMUNE DISEASE PROFILING
TABLE 42
US ADJUSTED RECIPROCAL TARIFF RATES
TABLE 43
IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 44
KEY REAGENTS & KITS AVAILABLE IN MARKET
TABLE 45
IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 46
IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 47
NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 48
EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 49
ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 50
LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 51
ELISA REAGENTS & KITS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 52
NORTH AMERICA: ELISA REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 53
EUROPE: ELISA REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 54
ASIA PACIFIC: ELISA REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 55
LATIN AMERICA: ELISA REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 56
RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 57
NORTH AMERICA: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 58
EUROPE: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 59
ASIA PACIFIC: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 60
LATIN AMERICA: RAPID TEST REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 61
ELISPOT REAGENTS & KITS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 62
NORTH AMERICA: ELISPOT REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 63
EUROPE: ELISPOT REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 64
ASIA PACIFIC: ELISPOT REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 65
LATIN AMERICA: ELISPOT REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 66
CLIA REAGENTS & KITS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 67
NORTH AMERICA: CLIA REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 68
EUROPE: CLIA REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 69
ASIA PACIFIC: CLIA REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 70
LATIN AMERICA: CLIA REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 71
IFA REAGENTS & KITS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 72
NORTH AMERICA: IFA REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 73
EUROPE: IFA REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 74
ASIA PACIFIC: IFA REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 75
LATIN AMERICA: IFA REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 76
WESTERN BLOT REAGENTS & KITS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 77
NORTH AMERICA: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 78
EUROPE: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 79
ASIA PACIFIC: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 80
LATIN AMERICA: WESTERN BLOT REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 81
OTHER REAGENTS & KITS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 82
NORTH AMERICA: OTHER REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 83
EUROPE: OTHER REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 84
ASIA PACIFIC: OTHER REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 85
LATIN AMERICA: OTHER REAGENTS & KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 86
KEY ANALYZERS AVAILABLE IN MARKET
TABLE 87
IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 88
NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 89
EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 90
ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 91
LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 92
IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 93
OPEN-ENDED SYSTEMS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 94
NORTH AMERICA: OPEN-ENDED SYSTEMS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 95
EUROPE: OPEN-ENDED SYSTEMS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 96
ASIA PACIFIC: OPEN-ENDED SYSTEMS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 97
LATIN AMERICA: OPEN-ENDED SYSTEMS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 98
CLOSED-ENDED SYSTEMS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 99
NORTH AMERICA: CLOSED-ENDED SYSTEMS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 100
EUROPE: CLOSED-ENDED SYSTEMS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 101
ASIA PACIFIC: CLOSED-ENDED SYSTEMS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 102
LATIN AMERICA: CLOSED-ENDED SYSTEMS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 103
IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION)
TABLE 104
RENTAL PURCHASE MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 105
NORTH AMERICA: RENTAL PURCHASE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 106
EUROPE: RENTAL PURCHASE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 107
ASIA PACIFIC: RENTAL PURCHASE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 108
LATIN AMERICA: RENTAL PURCHASE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 109
OUTRIGHT PURCHASE MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 110
NORTH AMERICA: OUTRIGHT PURCHASE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 111
EUROPE: OUTRIGHT PURCHASE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 112
ASIA PACIFIC: OUTRIGHT PURCHASE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 113
LATIN AMERICA: OUTRIGHT PURCHASE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 114
IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 115
IMMUNOASSAY TECHNOLOGY MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 116
NORTH AMERICA: IMMUNOASSAY TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 117
EUROPE: IMMUNOASSAY TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 118
ASIA PACIFIC: IMMUNOASSAY TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 119
LATIN AMERICA: IMMUNOASSAY TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 120
KEY ELISA TECHNOLOGIES AVAILABLE IN MARKET
TABLE 121
IMMUNOASSAY MARKET FOR ELISA, BY REGION, 2023–2030 (USD MILLION)
TABLE 122
NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 123
EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 124
ASIA PACIFIC: IMMUNOASSAY MARKET ELISA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 125
LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 126
IMMUNOASSAY MARKET FOR CLIA, BY REGION, 2023–2030 (USD MILLION)
TABLE 127
NORTH AMERICA: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 128
EUROPE: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 129
ASIA PACIFIC: IMMUNOASSAY MARKET CLIA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 130
LATIN AMERICA: IMMUNOASSAY MARKET FOR CLIA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 131
IMMUNOASSAY MARKET FOR IFA, BY REGION, 2023–2030 (USD MILLION)
TABLE 132
NORTH AMERICA: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 133
EUROPE: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 134
ASIA PACIFIC: IMMUNOASSAY MARKET IFA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 135
LATIN AMERICA: IMMUNOASSAY MARKET FOR IFA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 136
KEY RAPID TESTS AVAILABLE IN MARKET
TABLE 137
IMMUNOASSAY MARKET FOR RAPID TESTS, BY REGION, 2023–2030 (USD MILLION)
TABLE 138
NORTH AMERICA: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 139
EUROPE: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 140
ASIA PACIFIC: IMMUNOASSAY MARKET RAPID TESTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 141
LATIN AMERICA: IMMUNOASSAY MARKET FOR RAPID TESTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 142
KEY WESTERN BLOTTING SYSTEMS AVAILABLE IN MARKET
TABLE 143
IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY REGION, 2023–2030 (USD MILLION)
TABLE 144
NORTH AMERICA: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 145
EUROPE: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 146
ASIA PACIFIC: IMMUNOASSAY MARKET WESTERN BLOTTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 147
LATIN AMERICA: IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 148
IMMUNOASSAY MARKET FOR ELISPOT, BY REGION, 2023–2030 (USD MILLION)
TABLE 149
NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISPOT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 150
EUROPE: IMMUNOASSAY MARKET FOR ELISPOT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 151
ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISPOT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 152
LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISPOT, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 153
IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 154
NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 155
EUROPE: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 156
ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 157
LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 158
IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION)
TABLE 159
IMMUNOASSAY SPECIMEN MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 160
NORTH AMERICA: IMMUNOASSAY SPECIMEN MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 161
EUROPE: IMMUNOASSAY SPECIMEN MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 162
ASIA PACIFIC: IMMUNOASSAY SPECIMEN MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 163
LATIN AMERICA: IMMUNOASSAY SPECIMEN MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 164
IMMUNOASSAY MARKET FOR BLOOD, BY REGION, 2023–2030 (USD MILLION)
TABLE 165
NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 166
EUROPE: IMMUNOASSAY MARKET FOR BLOOD, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 167
ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 168
LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 169
IMMUNOASSAY MARKET FOR SALIVA, BY REGION, 2023–2030 (USD MILLION)
TABLE 170
NORTH AMERICA: IMMUNOASSAY MARKET FOR SALIVA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 171
EUROPE: IMMUNOASSAY MARKET FOR SALIVA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 172
ASIA PACIFIC: IMMUNOASSAY MARKET FOR SALIVA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 173
LATIN AMERICA: IMMUNOASSAY MARKET FOR SALIVA, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 174
IMMUNOASSAY MARKET FOR URINE, BY REGION, 2023–2030 (USD MILLION)
TABLE 175
NORTH AMERICA: IMMUNOASSAY MARKET FOR URINE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 176
EUROPE: IMMUNOASSAY MARKET FOR URINE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 177
ASIA PACIFIC: IMMUNOASSAY MARKET FOR URINE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 178
LATIN AMERICA: IMMUNOASSAY MARKET FOR URINE, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 179
IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY REGION, 2023–2030 (USD MILLION)
TABLE 180
NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 181
EUROPE: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 182
ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 183
LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 184
IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 185
IMMUNOASSAY APPLICATION MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 186
NORTH AMERICA: IMMUNOASSAY APPLICATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 187
EUROPE: IMMUNOASSAY APPLICATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 188
ASIA PACIFIC: IMMUNOASSAY APPLICATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 189
LATIN AMERICA: IMMUNOASSAY APPLICATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 190
IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)
TABLE 191
NORTH AMERICA: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 192
EUROPE: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 193
ASIA PACIFIC: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 194
LATIN AMERICA: IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 195
IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY REGION, 2023–2030 (USD MILLION)
TABLE 196
NORTH AMERICA: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 197
EUROPE: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 198
ASIA PACIFIC: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 199
LATIN AMERICA: IMMUNOASSAY MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 200
KEY PRODUCTS AVAILABLE FOR CARDIOLOGY APPLICATIONS
TABLE 201
IMMUNOASSAY MARKET FOR CARDIOLOGY, BY REGION, 2023–2030 (USD MILLION)
TABLE 202
NORTH AMERICA: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 203
EUROPE: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 204
ASIA PACIFIC: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 205
LATIN AMERICA: IMMUNOASSAY MARKET FOR CARDIOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 206
IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 207
NORTH AMERICA: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 208
EUROPE: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 209
ASIA PACIFIC: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 210
LATIN AMERICA: IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 211
IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2023–2030 (USD MILLION)
TABLE 212
NORTH AMERICA: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 213
EUROPE: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 214
ASIA PACIFIC: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 215
LATIN AMERICA: IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 216
INCREASING INCIDENCE OF CANCER, BY REGION, 2021 VS. 2030 VS. 2040 (MILLION)
TABLE 217
IMMUNOASSAY MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION)
TABLE 218
NORTH AMERICA: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 219
EUROPE: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 220
ASIA PACIFIC: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 221
LATIN AMERICA: IMMUNOASSAY MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 222
KEY PRODUCTS AVAILABLE FOR BONE & MINERAL DISORDERS
TABLE 223
IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 224
NORTH AMERICA: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 225
EUROPE: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 226
ASIA PACIFIC: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 227
LATIN AMERICA: IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 228
KEY PRODUCTS AVAILABLE FOR DRUG MONITORING & TESTING
TABLE 229
KEY IMMUNOASSAY PRODUCTS AVAILABLE FOR DRUG MONITORING & TESTING
TABLE 230
IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY REGION, 2023–2030 (USD MILLION)
TABLE 231
NORTH AMERICA: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 232
EUROPE: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 233
ASIA PACIFIC: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 234
LATIN AMERICA: IMMUNOASSAY MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 235
IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY REGION, 2023–2030 (USD MILLION)
TABLE 236
NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 237
EUROPE: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 238
ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 239
LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 240
KEY PRODUCTS AVAILABLE FOR NEWBORN SCREENING
TABLE 241
IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY REGION, 2023–2030 (USD MILLION)
TABLE 242
NORTH AMERICA: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 243
EUROPE: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 244
ASIA PACIFIC: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 245
LATIN AMERICA: IMMUNOASSAY MARKET FOR NEWBORN SCREENING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 246
IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
TABLE 247
NORTH AMERICA: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 248
EUROPE: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 249
ASIA PACIFIC: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 250
LATIN AMERICA: IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 251
IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 252
IMMUNOASSAY END USER MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 253
NORTH AMERICA: IMMUNOASSAY END USER MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 254
EUROPE: IMMUNOASSAY END USER MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 255
ASIA PACIFIC: IMMUNOASSAY END USER MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 256
LATIN AMERICA: IMMUNOASSAY END USER MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 257
IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023–2030 (USD MILLION)
TABLE 258
NORTH AMERICA: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 259
EUROPE: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 260
ASIA PACIFIC: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 261
LATIN AMERICA: IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 262
IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 263
NORTH AMERICA: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 264
EUROPE: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 265
ASIA PACIFIC: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 266
LATIN AMERICA: IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 267
IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY REGION, 2023–2030 (USD MILLION)
TABLE 268
NORTH AMERICA: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 269
EUROPE: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 270
ASIA PACIFIC: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 271
LATIN AMERICA: IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 272
IMMUNOASSAY MARKET FOR BLOOD BANKS, BY REGION, 2023–2030 (USD MILLION)
TABLE 273
NORTH AMERICA: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 274
EUROPE: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 275
ASIA PACIFIC: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 276
LATIN AMERICA: IMMUNOASSAY MARKET FOR BLOOD BANKS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 277
IMMUNOASSAY MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 278
NORTH AMERICA: KEY MACROINDICATORS
TABLE 279
NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 280
NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 281
NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 282
NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 283
NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION)
TABLE 284
NORTH AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 285
NORTH AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION)
TABLE 286
NORTH AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 287
NORTH AMERICA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 288
US: NUMBER OF IN VITRO DIAGNOSTICS TESTS CONDUCTED, 2022–2030 (BILLION UNITS)
TABLE 289
US: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 290
US: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 291
US: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 292
US: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION)
TABLE 293
US: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 294
US: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION)
TABLE 295
US: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 296
US: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 297
CANADA: ESTIMATED PREVALENCE OF DIABETES, 2024 VS. 2034
TABLE 298
CANADA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 299
CANADA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 300
CANADA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 301
CANADA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION)
TABLE 302
CANADA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 303
CANADA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION)
TABLE 304
CANADA: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 305
CANADA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 306
EUROPE: KEY MACROINDICATORS
TABLE 307
EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 308
EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 309
EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 310
EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 311
EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION)
TABLE 312
EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 313
EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION)
TABLE 314
EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 315
EUROPE: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 316
GERMANY: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 317
GERMANY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 318
GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 319
GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION)
TABLE 320
GERMANY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 321
GERMANY: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION)
TABLE 322
GERMANY: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 323
GERMANY: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 324
ITALY: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 325
ITALY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 326
ITALY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 327
ITALY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION)
TABLE 328
ITALY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 329
ITALY: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION)
TABLE 330
ITALY: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 331
ITALY: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 332
FRANCE: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 333
FRANCE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 334
FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 335
FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION)
TABLE 336
FRANCE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 337
FRANCE: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION)
TABLE 338
FRANCE: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 339
FRANCE: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 340
SPAIN: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 341
SPAIN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 342
SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 343
SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION)
TABLE 344
SPAIN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 345
SPAIN: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION)
TABLE 346
SPAIN: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 347
SPAIN: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 348
UK: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 349
UK: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 350
UK: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 351
UK: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION)
TABLE 352
UK: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 353
UK: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION)
TABLE 354
UK: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 355
UK: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 356
RUSSIA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 357
RUSSIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 358
RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 359
RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION)
TABLE 360
RUSSIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 361
RUSSIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION)
TABLE 362
RUSSIA: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 363
RUSSIA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 364
REST OF EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 365
REST OF EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 366
REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 367
REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION)
TABLE 368
REST OF EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 369
REST OF EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION)
TABLE 370
REST OF EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 371
REST OF EUROPE: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 372
ASIA PACIFIC: KEY MACROINDICATORS
TABLE 373
ASIA PACIFIC: IMMUNOASSAY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 374
ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 375
ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 376
ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 377
ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION)
TABLE 378
ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 379
ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION)
TABLE 380
ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 381
ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 382
JAPAN: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 383
JAPAN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 384
JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 385
JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION)
TABLE 386
JAPAN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 387
JAPAN: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION)
TABLE 388
JAPAN: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 389
JAPAN: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 390
CHINA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 391
CHINA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 392
CHINA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 393
CHINA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION)
TABLE 394
CHINA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 395
CHINA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION)
TABLE 396
CHINA: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 397
CHINA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 398
INDIA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 399
INDIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 400
INDIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 401
INDIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION)
TABLE 402
INDIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 403
INDIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION)
TABLE 404
INDIA: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 405
INDIA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 406
AUSTRALIA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 407
AUSTRALIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 408
AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 409
AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION)
TABLE 410
AUSTRALIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 411
AUSTRALIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION)
TABLE 412
AUSTRALIA: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 413
AUSTRALIA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 414
SOUTH KOREA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 415
SOUTH KOREA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 416
SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 417
SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION)
TABLE 418
SOUTH KOREA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 419
SOUTH KOREA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION)
TABLE 420
SOUTH KOREA: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 421
SOUTH KOREA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 422
INDONESIA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 423
INDONESIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 424
INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 425
INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION)
TABLE 426
INDONESIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 427
INDONESIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION)
TABLE 428
INDONESIA: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 429
INDONESIA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 430
REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 431
REST OF ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 432
REST OF ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 433
REST OF ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION)
TABLE 434
REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 435
REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION)
TABLE 436
REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 437
REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 438
LATIN AMERICA: KEY MACROINDICATORS
TABLE 439
LATIN AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 440
LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 441
LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 442
LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 443
LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION)
TABLE 444
LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 445
LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION)
TABLE 446
LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 447
LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 448
BRAZIL: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 449
BRAZIL: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 450
BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 451
BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION)
TABLE 452
BRAZIL: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 453
BRAZIL: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION)
TABLE 454
BRAZIL: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 455
BRAZIL: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 456
MEXICO: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 457
MEXICO: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 458
MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 459
MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION)
TABLE 460
MEXICO: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 461
MEXICO: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION)
TABLE 462
MEXICO: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 463
MEXICO: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 464
REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 465
REST OF LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 466
REST OF LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 467
REST OF LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION)
TABLE 468
REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 469
REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION)
TABLE 470
REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 471
REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 472
MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)
TABLE 473
MIDDLE EAST & AFRICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 474
MIDDLE EAST & AFRICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 475
MIDDLE EAST & AFRICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2023–2030 (USD MILLION)
TABLE 476
MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 477
MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2023–2030 (USD MILLION)
TABLE 478
MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 479
MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 480
OVERVIEW OF KEY STRATEGIES DEPLOYED BY MAJOR PLAYERS IN IMMUNOASSAY MARKET
TABLE 481
IMMUNOASSAY MARKET: DEGREE OF COMPETITION
TABLE 482
IMMUNOASSAY MARKET: REGION FOOTPRINT
TABLE 483
IMMUNOASSAY MARKET: PRODUCT FOOTPRINT
TABLE 484
IMMUNOASSAY MARKET: SPECIMEN FOOTPRINT
TABLE 485
IMMUNOASSAY MARKET: LIST OF KEY STARTUPS/SME PLAYERS
TABLE 486
IMMUNOASSAY MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/ SME PLAYERS, BY REGION
TABLE 487
IMMUNOASSAY MARKET: PRODUCT LAUNCHES/APPROVALS/ENHANCEMENTS, JANUARY 2022–JULY 2025
TABLE 488
IMMUNOASSAY MARKET: DEALS, JANUARY 2022–JULY 2025
TABLE 489
ABBOTT: COMPANY OVERVIEW
TABLE 490
ABBOTT: PRODUCTS OFFERED
TABLE 491
ABBOTT: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025
TABLE 492
ABBOTT: DEALS, JANUARY 2022–JUNE 2025
TABLE 493
ABBOTT: EXPANSIONS, JANUARY 2022–JUNE 2025
TABLE 494
F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
TABLE 495
F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
TABLE 496
F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025
TABLE 497
F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022–JUNE 2025
TABLE 498
F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2022–JUNE 2025
TABLE 499
SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
TABLE 500
SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
TABLE 501
SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025
TABLE 502
SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022–JUNE 2025
TABLE 503
SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2022–JUNE 2025
TABLE 504
DANAHER: COMPANY OVERVIEW
TABLE 505
DANAHER: PRODUCTS OFFERED
TABLE 506
DANAHER: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025
TABLE 507
DANAHER: DEALS, JANUARY 2022–JUNE 2025
TABLE 508
DANAHER: EXPANSIONS, JANUARY 2022–JUNE 2025
TABLE 509
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 510
THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
TABLE 511
THERMO FISHER SCIENTIFIC INC.: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025
TABLE 512
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–JUNE 2025
TABLE 513
REVVITY: COMPANY OVERVIEW
TABLE 514
REVVITY: PRODUCTS OFFERED
TABLE 515
REVVITY: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025
TABLE 516
REVVITY: OTHER DEVELOPMENTS, JANUARY 2022–JUNE 2025
TABLE 517
BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW
TABLE 518
BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED
TABLE 519
BECTON, DICKINSON AND COMPANY (BD): EXPANSIONS, JANUARY 2022–JUNE 2025
TABLE 520
DIASORIN S.P.A.: COMPANY OVERVIEW
TABLE 521
DIASORIN S.P.A.: PRODUCTS OFFERED
TABLE 522
DIASORIN S.P.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025
TABLE 523
DIASORIN S.P.A.: DEALS, JANUARY 2022–JUNE 2025
TABLE 524
BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
TABLE 525
BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
TABLE 526
BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2022–JUNE 2025
TABLE 527
BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022–JUNE 2025
TABLE 528
QUIDELORTHO CORPORATION: COMPANY OVERVIEW
TABLE 529
QUIDELORTHO CORPORATION: PRODUCTS OFFERED
TABLE 530
QUIDELORTHO CORPORATION: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025
TABLE 531
QUIDELORTHO CORPORATION: DEALS, JANUARY 2022–JUNE 2025
TABLE 532
QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2022–JUNE 2025
TABLE 533
BIOMÉRIEUX: COMPANY OVERVIEW
TABLE 534
BIOMÉRIEUX: PRODUCTS OFFERED
TABLE 535
BIOMÉRIEUX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025
TABLE 536
BIOMÉRIEUX: DEALS, JANUARY 2022–JUNE 2025
TABLE 537
QIAGEN: COMPANY OVERVIEW
TABLE 538
QIAGEN: PRODUCTS OFFERED
TABLE 539
QIAGEN: DEALS, JANUARY 2022–JUNE 2025
TABLE 540
SYSMEX CORPORATION: COMPANY OVERVIEW
TABLE 541
SYSMEX CORPORATION: PRODUCTS OFFERED
TABLE 542
SYSMEX CORPORATION: DEALS, JANUARY 2022–JUNE 2025
TABLE 543
SYSMEX CORPORATION: EXPANSIONS, JANUARY 2022–JUNE 2025
TABLE 544
AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
TABLE 545
AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
TABLE 546
AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JUNE 2025
TABLE 547
AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022–JUNE 2025
TABLE 548
AGILENT TECHNOLOGIES, INC.: OTHER DEVELOPMENTS, JANUARY 2022–JUNE 2025
TABLE 549
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW
TABLE 550
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: PRODUCTS OFFERED
TABLE 551
MERCK KGAA: COMPANY OVERVIEW
TABLE 552
MERIDIAN BIOSCIENCE: COMPANY OVERVIEW
TABLE 553
BIO-TECHNE: COMPANY OVERVIEW
TABLE 554
CELLABS: COMPANY OVERVIEW
TABLE 555
ABNOVA CORPORATION: COMPANY OVERVIEW
TABLE 556
J. MITRA & CO. PVT. LTD.: COMPANY OVERVIEW
TABLE 557
TOSOH CORPORATION (TOSOH BIOSCIENCES): COMPANY OVERVIEW
TABLE 558
CELL SCIENCES: COMPANY OVERVIEW
TABLE 559
ENZO BIOCHEM INC.: COMPANY OVERVIEW
TABLE 560
CREATIVE DIAGNOSTICS: COMPANY OVERVIEW
TABLE 561
BOSTER BIOLOGICAL TECHNOLOGY: COMPANY OVERVIEW
TABLE 562
ELABSCIENCE BIONOVATON INC.: COMPANY OVERVIEW
TABLE 563
WAK-CHEMIE MEDICAL GMBH: COMPANY OVERVIEW
TABLE 564
SERA CARE: COMPANY OVERVIEW
TABLE 565
EPITOPE DIAGNOSTICS, INC.: COMPANY OVERVIEW
TABLE 566
KAMIYA BIOMEDICAL COMPANY: COMPANY OVERVIEW
TABLE 567
GYROS PROTEIN TECHNOLOGIES AB: COMPANY OVERVIEW
TABLE 568
TRIVITRON HEALTHCARE: COMPANY OVERVIEW
TABLE 569
INBIOS INTERNATIONAL, INC.: COMPANY OVERVIEW
TABLE 570
MACCURA BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW
LIST OF FIGURES
FIGURE 1
IMMUNOASSAY MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2
IMMUNOASSAY MARKET: YEARS CONSIDERED
FIGURE 3
IMMUNOASSAY MARKET: RESEARCH DESIGN
FIGURE 4
IMMUNOASSAY MARKET: KEY DATA FROM SECONDARY SOURCES
FIGURE 5
IMMUNOASSAY MARKET: KEY PRIMARY SOURCES
FIGURE 6
IMMUNOASSAY MARKET: KEY INSIGHTS FROM INDUSTRY EXPERTS
FIGURE 7
BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
FIGURE 8
BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 9
IMMUNOASSAY MARKET: COMPANY REVENUE ESTIMATION (REVENUE SHARE ANALYSIS)
FIGURE 10
IMMUNOASSAY MARKET: CAGR PROJECTIONS (SUPPLY-SIDE ANALYSIS)
FIGURE 11
IMMUNOASSAY MARKET: TOP-DOWN APPROACH
FIGURE 12
IMMUNOASSAY MARKET: DATA TRIANGULATION METHODOLOGY
FIGURE 13
IMMUNOASSAY MARKET, BY PRODUCT, 2025 VS. 2030 (USD BILLION)
FIGURE 14
IMMUNOASSAY MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD BILLION)
FIGURE 15
IMMUNOASSAY MARKET, BY SPECIMEN, 2025 VS. 2030 (USD BILLION)
FIGURE 16
IMMUNOASSAY MARKET, BY APPLICATION, 2025 VS. 2030 (USD BILLION)
FIGURE 17
IMMUNOASSAY MARKET, BY END USER, 2025 VS. 2030 (USD BILLION)
FIGURE 18
REGIONAL SNAPSHOT OF IMMUNOASSAY MARKET
FIGURE 19
FAVORABLE REGULATORY SCENARIO AND HIGH PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
FIGURE 20
US AND REAGENTS & KITS COMMANDED LARGEST SHARE OF NORTH AMERICAN IMMUNOASSAY MARKET IN 2024
FIGURE 21
CHINA TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 22
ASIA PACIFIC TO WITNESS HIGHEST CAGR DURING STUDY PERIOD
FIGURE 23
IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 24
RATE OF INCREASE IN INCIDENCE OF DIABETES GLOBALLY (IN MILLION)
FIGURE 25
US: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES
FIGURE 26
CANADA: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES
FIGURE 27
JAPAN: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES
FIGURE 28
INDIA: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES
FIGURE 29
MEXICO: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES
FIGURE 30
BRAZIL: REGULATORY PROCESS FOR IN-VIRTO DIAGNOSTIC DEVICES
FIGURE 31
TOP 10 PATENT OWNERS/APPLICANTS IN IMMUNOASSAY MARKET, JANUARY 2015–DECEMBER 2024
FIGURE 32
IMMUNOASSAY MARKET: VALUE CHAIN ANALYSIS
FIGURE 33
IMMUNOASSAY MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 34
IMMUNOASSAY MARKET: ECOSYSTEM ANALYSIS
FIGURE 35
IMMUNOASSAY MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 36
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY END USER
FIGURE 37
KEY BUYING CRITERIA FOR TOP END USERS
FIGURE 38
IMMUNOASSAY MARKET: TRENDS/DISTRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 39
IMMUNOASSAY MARKET: FUNDING AND NUMBER OF DEALS, 2018−2025 (USD MILLION)
FIGURE 40
MARKET POTENTIAL OF AI/GEN AI IN ENHANCING IMMUNOASSAY DIAGNOSIS AND TREATMENT PLANNING
FIGURE 41
NORTH AMERICA: IMMUNOASSAY MARKET SNAPSHOT
FIGURE 42
ASIA PACIFIC: IMMUNOASSAY MARKET SNAPSHOT
FIGURE 43
REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNOASSAY MARKET (2020–2024)
FIGURE 44
MARKET SHARE ANALYSIS OF KEY PLAYERS IN IMMUNOASSAY MARKET (2024)
FIGURE 45
IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 46
IMMUNOASSAY MARKET: COMPANY FOOTPRINT
FIGURE 47
IMMUNOASSAY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 48
EV/EBITDA OF KEY VENDORS, 2025
FIGURE 49
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2025
FIGURE 50
IMMUNOASSAY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 51
ABBOTT: COMPANY SNAPSHOT
FIGURE 52
F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
FIGURE 53
SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT
FIGURE 54
DANAHER: COMPANY SNAPSHOT
FIGURE 55
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
FIGURE 56
REVVITY: COMPANY SNAPSHOT
FIGURE 57
BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT
FIGURE 58
DIASORIN S.P.A.: COMPANY SNAPSHOT
FIGURE 59
BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
FIGURE 60
QUIDELORTHO CORPORATION: COMPANY SNAPSHOT
FIGURE 61
BIOMÉRIEUX: COMPANY SNAPSHOT
FIGURE 62
QIAGEN: COMPANY SNAPSHOT
FIGURE 63
SYSMEX CORPORATION: COMPANY SNAPSHOT
FIGURE 64
AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
FIGURE 65
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT
Methodology
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global immunoassay market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
Secondary research was used primarily to identify & collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources used for this study include annual reports, SEC filings, investor presentations, World Health Organization (WHO), United States Food and Drug Administration (US FDA), National Center for Biotechnology Information (NCBI), Health Canada, European Medicines Agency (EMA), and Centers for Disease Control and Prevention (CDC). These sources also obtained key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives of major market companies, and industry consultants, to gather and verify critical qualitative and quantitative information and evaluate the market prospects. Several primary sources from both the supply and demand sides of the market were interviewed to collect qualitative and quantitative data. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were employed to estimate and verify the total size of the immunoassay market. These methods were also widely used to determine the sizes of various subsegments within the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
The total market was divided into several segments and subsegments after determining the overall market size from the estimation process. Where applicable, data triangulation and market breakdown techniques were used to complete the overall market analysis and obtain precise statistics for all segments and subsegments. The data was triangulated by examining various factors and trends from both the demand and supply perspectives.
Market Definition
An immunoassay is a test that uses biochemistry to detect the presence or level of an analyte, which is a large protein or antibody produced in response to an infection. These assays are highly versatile and can be adapted to many formats based on user needs. Immunoassays have become popular and well-established procedures in laboratories. They rapidly and easily provide precise and accurate results. This technique is mainly used in clinical diagnostics, drug monitoring, drug discovery, and food testing.
Stakeholders
- Manufacturers and vendors of immunoassay instruments and consumables
- Immunoassay product manufacturers
- Diagnostic associations
- Research associations involved in infectious and chronic disease research
- Various research and consulting firms
- Distributors of immunoassay instruments and consumables
- Contract research manufacturers of immunoassays
- Healthcare institutions
- Clinical laboratories
Report Objectives
- To define, describe, and forecast the global immunoassay market by product, technology, specimen, application, end user, and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, and opportunities)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall immunoassay market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa
- To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- Track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the immunoassay market.
- To analyze and provide funding & investment activities, brand/product comparative analysis, and vendor valuation & financial metrics of the immunoassay market.
Customization Options
With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:
Portfolio Assessment
- Product Matrix gives a detailed comparison of the product portfolios of the top five companies.
Company Information
- • Detailed analysis and profiling of additional market players (up to five).
Geographical Analysis
- A further breakdown of the Rest of European immunoassay market into countries
- A further breakdown of the Rest of Asia Pacific immunoassay market into countries
- A further breakdown of the Rest of Latin American immunoassay market into countries
Key Questions Addressed by the Report
Who are the key players in the immunoassay market?
Key players include Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Danaher (US), Revvity (US), Becton, Dickinson and Company (BD) (US), DiaSorin S.p.A. (Italy), Bio-Rad Laboratories, Inc. (US), QuidelOrtho Corporation (US), bioMérieux (France), QIAGEN (Netherlands), Sysmex Corporation (Japan), Agilent Technologies, Inc. (US), Shenzhen Mindray Bio-medical Electronics Co., Ltd. (China), and Merck KGaA (Germany).
What are the major technologies used in immunoassays?
Major technologies include ELISA, CLIA, IFA, rapid tests, ELISpot, western blotting, and other platforms. ELISA held the largest market share in 2024, followed by rapid tests.
Which specimen type segment of the immunoassay market is expected to witness the highest growth?
The blood specimen segment is expected to record the highest growth due to its superior diagnostic accuracy.
Which end user segment of the immunoassay market is expected to witness the highest growth?
Hospitals & clinics accounted for both the largest share and the highest growth in 2024 owing to high patient footfall for diagnostic and therapeutic services.
What is the market size for the residual DNA market?*
The global immunoassay market is projected to reach USD 47.7 billion by 2030, up from USD 35.5 billion in 2025, at a CAGR of 6.1%.
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Immunoassay Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationGrowth opportunities and latent adjacency in Immunoassay Market
Before You Go
Expand Beyond Immunoassay Market
Explore the top 20 industries influencing your market growth
Human and AI Powered Market Intelligence
Find Untapped Markets
Harrison
Oct, 2022
What are the major revenue pockets in Immunoassay Market? .
Brock
Oct, 2022
What are the latest growth trends in immunoassay industry?.
Liam
Oct, 2022
Which segment ot provide highest revenue expansion opportynity?.